![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
48 Week Bone Marker Changes in Dolutegravir (DTG; GSK1349572) Plus Abacavir/Lamivudine (ABC/3TC) vs Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): The SINGLE Trial
|
|
|
Reported by Jules Levin
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, CO
P Tebas,1P Kumar,2C Hicks,3C Granier,4B Wynne,5K Pappa,6S Min61University of Pennsylvania, Philadelphia, PA, USA; 2Georgetown University School of Medicine, Washington, DC, USA; 3Duke University Medical Center, Durham, NC, USA; 4-6GlaxoSmithKline, 4London, UK; 5Philadelphia, PA, USA; 6Research Triangle Park, NC, USA
![ICAAC4.gif](../images/091313/091313-1/ICAAC4.gif)
![ICAAC5.gif](../images/091313/091313-1/ICAAC5.gif)
![ICAAC6.gif](../images/091313/091313-1/ICAAC6.gif)
![ICAAC7.gif](../images/091313/091313-1/ICAAC7.gif)
![ICAAC8.gif](../images/091313/091313-1/ICAAC8.gif)
![ICAAC9.gif](../images/091313/091313-1/ICAAC9.gif)
![ICAAC10.gif](../images/091313/091313-1/ICAAC10.gif)
![ICAAC11.gif](../images/091313/091313-1/ICAAC11.gif)
![ICAAC12.gif](../images/091313/091313-1/ICAAC12.gif)
![Proport.gif](../images/091413/091413-5/Proport.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|